Loutan L, Bovier P, Althaus B, Glück R
Department of Medicine, Hôpital Cantonal Universitaire de Genève, Switzerland.
Lancet. 1994 Feb 5;343(8893):322-4. doi: 10.1016/s0140-6736(94)91162-2.
Immunopotentiating reconstituted influenza virosomes (IRIV) are efficient carrier systems for small virion particles such as hepatitis A virus (HAV). We evaluated immunogenicity and tolerability of an IRIV-HAV vaccine and the effectiveness of a booster by immunising 104 healthy HAV seronegative volunteers. A single dose was highly immunogenic, since 98% of volunteers had seroconverted after 2 weeks. Anti-HAV titres remained high, with 100% seroconversion rate 1 year later, when the booster was given. The vaccine was effective, with a 22-fold increase in geometric mean titres 1 month later. No serious adverse reactions were observed.
